MITHRA PHARMACEUTICALS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.233 EUR | +5.67% |
|
+1.75% | -81.42% |
| Sales 2023 | 40.16M 42.74M | Sales 2024 * | 43.9M 46.73M | Capitalization | 16.1M 17.14M |
|---|---|---|---|---|---|
| Net income 2023 | -174M -185M | Net income 2024 * | -55M -58.54M | EV / Sales 2023 | 2.16 x |
| Net Debt 2023 * | 238M 253M | Net Debt 2024 * | 166M 177M | EV / Sales 2024 * | 4.16 x |
| P/E ratio 2023 * |
-0.17
x | P/E ratio 2024 * |
-
| Employees | 270 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 81.67% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.67% | ||
| 1 week | +2.42% | ||
| Current month | -16.49% | ||
| 1 month | +14.22% | ||
| 3 months | -79.91% | ||
| 6 months | -79.20% | ||
| Current year | -81.42% |
1 week
0.22
0.23
1 month
0.210.29
Current year
0.201.36
1 year
0.203.87
3 years
0.2027.05
5 years
0.2032.96
10 years
0.2039.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 17-02-22 | |
Stijn Vlaminck
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-30 |
Graham Dixon
CTO | Chief Tech/Sci/R&D Officer | 63 | 19-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jacques Galloy
BRD | Director/Board Member | 53 | 23-05-28 |
Christian Homsy
CHM | Chairman | 65 | 23-05-28 |
Valérie Gordenne
BRD | Director/Board Member | 51 | 21-05-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.233 | +5.67% | 36,373 |
| 24-04-17 | 0.2205 | -4.55% | 184,870 |
| 24-04-16 | 0.231 | +0.43% | 20,944 |
| 24-04-15 | 0.23 | +1.77% | 55,582 |
| 24-04-12 | 0.226 | -1.31% | 59,967 |
Real-time Euronext Bruxelles, April 18, 2024 at 11:35 am EDT
More quotes
Mithra Pharmaceuticals S.A. is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.
Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, the Company is now focusing on its second product Donesta®, the next-generation hormone therapy.
Mithra Pharmaceuticals S.A. also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
0.233
EUR
Average target price
0.11
EUR
Spread / Average Target
-52.79%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -81.42% | 16.21M | |
| -5.32% | 84.57B | |
| +3.95% | 39.93B | |
| -26.37% | 27.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B |
- Stock Market
- Equities
- MITRA Stock
